This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.

This study has been completed.
Synteract, Inc.
Thywill Latam Solutions SRL
OCASA Soluciones Logísticas S.A.
Worldwide Clinical Trials
Information provided by:
Mast Therapeutics, Inc. Identifier:
First received: February 6, 2007
Last updated: January 19, 2012
Last verified: January 2012
This study was a randomized, single dose crossover comparison of the investigational product with a Reference Product (vinorelbine tartrate injection, NAVELBINE®). The primary objective was to demonstrate the equivalence of ANX-530 and the Reference Product, NAVELBINE.

Condition Intervention Phase
Breast Cancer Non-small Cell Lung Cancer Non-Hodgkins Lymphoma Drug: Vinorelbine Tartrate Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.

Resource links provided by NLM:

Further study details as provided by Mast Therapeutics, Inc.:

Primary Outcome Measures:
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: 0-144 hours post dose ]
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 0-144 hours post-dose ]
  • Area Under the Plasma Concentratio-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast) [ Time Frame: 0-144 hours post-dose ]
    Determined Using the Linear Trapezoidal Rule

  • Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) [ Time Frame: 0-144 hours post-dose ]
    AUCinf = AUClast + (Clast/lamda z)

  • Percentage of AUCinf Based on Extrapolation (AUCextrap) [ Time Frame: 0-144 hours post-dose ]
  • Observed Elimination Rate Constant Associated With the Terminal Portion of the Curve (λ z) [ Time Frame: 0-144 hours post-dose ]
    Estimated via linear regression of the time versus log concentration

  • Observed Terminal Elimination Half-Life (t1/2) [ Time Frame: 0-144 hours post-dose ]
    t1/2 = [ln(2)/λ z]

  • Time of Last Measurable Concentration (Tlast) [ Time Frame: 0-144 hours post-dose ]
  • Last Quantifiable Drug Concentration (Clast) [ Time Frame: 0-144 hours post-dose ]
  • Mean Residence Time (MRTinf) [ Time Frame: 0-144 hours post-dose ]
    MRT = (AUMCinf)/(AUCinf)

Enrollment: 31
Study Start Date: February 2007
Study Completion Date: December 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Vinorelbine Tartrate
    Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
    Other Names:
    • Exelbine (proposed)
    • ANX-530
Detailed Description:
ANX-530 (vinorelbine tartrate injectable emulsion), an investigational drug, is an oil-in-water emulsion of vinorelbine tartrate composed of an oil phase and emulsifier dispersed in an aqueous solution. ADVENTRX Pharmaceuticals, Inc. of San Diego, California, developed ANX-530 as a vinorelbine tartrate formulation to be used in clinical settings where Vinorelbine Tartrate Injection (NAVELBINE) is indicated. Nonclinical toxicology studies suggest either equivalent or less toxicity of ANX-530 compared to Reference Product. In particular, ANX-530 caused less vein toxicity in a rabbit vein irritation model, suggesting ANX-530 could potentially cause less venous irritation than NAVELBINE in a clinical setting. ADVENTRX is investigating whether ANX-530 could substitute for NAVELBINE in these settings.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years.
  • Advanced cancer potentially sensitive to vinorelbine:
  • Breast cancer.
  • Stage 3 or 4 non-small cell lung cancer.
  • Non-Hodgkins lymphoma.
  • Cancer of other histologic type, sensitive to vinca alkaloids.
  • Rare tumor type with no standard treatment, for which single agent vinorelbine is appropriate therapy.
  • Failure of standard treatment(s) of the tumor.
  • Life expectancy of at least three months.
  • ECOG performance level 0-2 or Karnofsky score 100-70.
  • Hematological and serum chemistry results with defined ranges.
  • Willingness and ability to provide written informed consent.

Exclusion Criteria:

  • Pregnancy or lactation. In a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no use of reliable contraception, at baseline. A postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months.
  • Previous treatment with vinorelbine or mitomycin.
  • Any history suggesting or demonstrating resistance to, lack of response to, or intolerance of any prior vinca alkaloid treatment.
  • Active infection.
  • Prior anticancer therapy completed within four weeks prior to the first day of study treatment.
  • Failure to have recovered from any toxicity of previous cancer treatment (patients with alopecia will not be excluded).
  • Participation in another experimental drug study within four weeks prior to the first day of study treatment.
  • Requirement for any concomitant chemotherapeutic agent other than the study medication.
  • Any investigator judgment that the individual would not be an appropriate study subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00432562

Clinical Investigative Site
Buenos Aires, Argentina
Clinical Investigative Site
Mendoza, Argentina
Clinical Investigative Site
Rosario, Argentina
Clinical Investigative Site
Santa Fe, Argentina
Clinical Investigative Site
Tucuman, Argentina
Sponsors and Collaborators
Mast Therapeutics, Inc.
Synteract, Inc.
Thywill Latam Solutions SRL
OCASA Soluciones Logísticas S.A.
Worldwide Clinical Trials
Principal Investigator: Lino Arboit, M.D. Fundación Centro Oncológico de Integración Regional - COIR.
Principal Investigator: Gerardo F Arroyo, M.D. Hospital Privado De Santa Clara De Asis
Principal Investigator: Cesar R Blajman, M.D. Isis Clínica Especializada
Principal Investigator: Matias Chacon, M.D. Instituto Médico Espcializado Alexander Fleming
Principal Investigator: Luis E Fein, M.D. Centro Oncológico
Principal Investigator: Hugo R. Requejo, M.D. Hospital Regional De Concepción
Principal Investigator: Edgar P Quintana, M.D. CIMA Salud
  More Information

Responsible Party: Chief Executive Officer, Adventrx Pharmaceuticals, Inc. Identifier: NCT00432562     History of Changes
Other Study ID Numbers: 530-01
Study First Received: February 6, 2007
Results First Received: January 19, 2012
Last Updated: January 19, 2012

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lymphoma, Non-Hodgkin
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017